Esperion Therapeutics Inc (NASDAQ:ESPR) CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was purchased at an average cost of $43.48 per share, for a total transaction of $217,400.00. Following the completion of the transaction, the chief executive officer now owns 56,163 shares of the company’s stock, valued at $2,441,967.24. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Shares of ESPR stock traded up $1.05 during trading on Thursday, hitting $44.23. 414,029 shares of the company were exchanged, compared to its average volume of 598,647. The stock has a market cap of $1.16 billion, a P/E ratio of -5.87 and a beta of 2.17. Esperion Therapeutics Inc has a twelve month low of $33.06 and a twelve month high of $79.30.
Several research analysts have recently weighed in on ESPR shares. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. ValuEngine downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. BidaskClub raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 4th. Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Thursday, December 13th. They issued a “sell” rating and a $45.00 target price on the stock. Finally, Northland Securities reissued a “buy” rating and issued a $65.00 target price on shares of Esperion Therapeutics in a research report on Friday, March 1st. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $73.08.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2019/03/21/insider-buying-esperion-therapeutics-inc-espr-ceo-purchases-5000-shares-of-stock.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Stock Split
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.